Correction to: Cardiovasc Diabetol (2021) 20:91 https://doi.org/10.1186/s12933-021-01276-9

Following publication of the original article [1], the authors regret the errors of the original data display in the forest plots, which has been corrected with this erratum.

For the analysis of amputation, in DAPA-CKD study, there should be 35 amputation events out of 2149 total events in SGLT2i treatment arm, and 39 amputation events out of 2149 total events in control treatment arm. And in DELIGHT study, there should be 1 amputation event out of 145 total events in SGLT2i treatment arm.

For the analysis of PAD and DF, there should be 573 total events in SGLT2i treatment arm in DEPICT-1 study, and there should be 419 total events in SGLT2i treatment arm in EMPA Barnett 2014, according to the data from Clinicaltrial.gov.

The data has been updated with in the new Fig. 1a and Fig. 1b. Some results from the sensitivity analyses were slightly changed and have been also updated in the new Table 1. The results of meta-regression remained unchanged in current reserved decimal digits. Such mild changes did not cause any substantial influence to the conclusion and clinical significance of our study.

Fig. 1
figure 1

The risk of amputation and PAD in patients with SGLT2i treatment. a The risk of amputation in patients with SGLT2i treatment. b The risk of PAD in patients with SGLT2i treatment. PAD peripheral arterial disease, SGLT2i sodium glucose co-transporter 2 inhibitor

Full size image
Table 1 Risk of amputation, PAD and DF events in patients with SGLT2i treatment
Full size table

The contents in the abstract and main text have also been updated. All revisions are highlighted in bold fonts as follows.

In the result section of the abstract, the revision is shown as “The numbers of SGLT2i users versus non-SGLT2i users in the analyses of amputation, PAD and DF were 40,765/33,406, 36,701/28,676 and 32,043/25,558 respectively”.

In the Included studies section of the main text, the revision is shown as “The numbers of SGLT2i users versus non-SGLT2i users in the analyses of amputation, PAD and DF were 40,765/33,406, 36,701/28,676 and 32,043/25,558 respectively”.

In the Risk of amputation, PAD and DF in patients with SGLT2i treatment section of the main text, the revisions are shown as: (1) “Compared with non-SGLT2i users, the risk of amputation (OR = 1.21, 95% CI 1.06 to 1.37, P = 0.004) (Fig. 1a) ……”; (2) “As for study population, the incidence of amputation (OR = 1.24, 95% CI 1.08 to 1.42, P = 0.002) and PAD (OR = 1.22, 95% CI 1.03 to 1.45, P = 0.02) were significantly increased in SGLT2i users versus non-SGLT2i users……”; (3) “Moreover, the risk of amputation (OR = 1.20, 95% CI 1.05 to 1.36, P = 0.006) and the risk of PAD (OR = 1.22, 95% CI 1.03 to 1.44, P = 0.02) were significantly higher in RCTs with study duration longer than 52 weeks……”.